Several established products saw sizable declines. Peters said glucagon sales fell 45% to $14.1 million , citing increased competition and a market shift toward ready-to-use products such as BAQSIMI. Epinephrine sales declined 9% to $17.1 million due to increased competition for the company’s epinephrine multi-dose vial products, partially offset by higher unit volumes for epinephrine pre-filled syringes amid supplier shortages during the quarter.Newer products also began contributing, including $4.4 millio ...

Key Takeaways CRMD's Q4 results are expected to reflect strong DefenCath sales and incremental Melinta contribution.CorMedix expects 2026 revenues of $300-$320M, with DefenCath sales weighted to early 2026.CRMD's preliminary Q4 sales of about $127M reflect DefenCath momentum and Melinta contributions.We expect investors to focus on the sales performance of CorMedix’s (CRMD) lead product, DefenCath (taurolidine plus heparin), when the company reports fourth-quarter and full-year 2025 results. The Zacks Conse ...

Key Takeaways CorMedix's shares fell 27% in 3 months after issuing a cautious 2026 outlook for DefenCath.CRMD expects 2026 revenues of $300-$320M, with DefenCath sales weighted to early 2026.CorMedix acquired Melinta, adding seven therapies to diversify its commercial portfolio beyond DefenCath.Shares of CorMedix (CRMD) have witnessed a sharp decline over the past three months. A key reason for the stocks’ decline during this time has been the company’s bearish 2026 financial outlook. In January, management ...

Core Insights - CorMedix's primary revenue source is DefenCath, the first and only antimicrobial catheter lock solution approved in the U.S., aimed at reducing catheter-related bloodstream infections (CRBSIs) in adult patients undergoing chronic hemodialysis [1][3] - DefenCath recorded $167.6 million in net sales during the first nine months of 2025, with expectations for continued strong sales growth in the fourth quarter due to increased utilization by outpatient dialysis customers [2][5] - CorMedix reported preliminary net revenues of approximately $127 million for Q4 2025 and $310 million for the full year, with 2026 revenue guidance set at $300-$320 million, including $150-$170 million from DefenCath [3][5] Business Diversification - CorMedix acquired Melinta Therapeutics in August 2025, adding seven approved therapies to its portfolio and generating $12.8 million in revenues in Q3 2025, which helps reduce reliance on DefenCath [4][5] Competitive Landscape - CorMedix faces significant competition from established players in the heparin market, including Pfizer, Amphastar Pharmaceuticals, B. Braun, Baxter, and Fresenius Kabi USA, which could pose risks to its market position [6][7][8] - The potential entry of larger companies into the CRBSI prevention space could increase competitive pressure on CorMedix [8][9] Stock Performance and Valuation - CorMedix's stock has decreased by 33.1% over the past six months, underperforming the industry growth of 23.9% [11] - The company's shares are trading at a price/book ratio of 1.62, below the industry average of 3.73, indicating a discount relative to the sector [12] Earnings Estimates - Earnings estimates for CorMedix have been revised downwards, with 2025 estimates decreasing from $2.85 to $2.78 per share and 2026 estimates dropping from $2.37 to $1.30 [13]

Core Insights - CorMedix (CRMD) shares have dropped 31% in the past month due to a conservative 2026 financial outlook, contrasting with a 4.3% rise in the industry [1][9][22] - The company's lead product, DefenCath, is expected to see slower growth than previously anticipated, impacting investor sentiment [1][3][9] Financial Performance - In the first nine months of 2025, DefenCath generated $167.6 million in net sales, indicating strong initial market uptake [6] - CorMedix reported preliminary unaudited pro forma net revenues of approximately $400 million for 2025, aligning with its guidance of $390 million to $410 million [7] - For 2026, management has guided revenues of $300-$320 million, with DefenCath sales projected at $150-$170 million [10][11] Product and Market Position - DefenCath is the only FDA-approved antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections in patients undergoing chronic hemodialysis [3][6] - The product is protected by patents until 2033, and CorMedix is exploring label expansion into total parenteral nutrition [6] Strategic Developments - CorMedix acquired Melinta Therapeutics for $300 million, adding seven approved therapies to its portfolio and diversifying revenue sources [12][13] - The acquisition is expected to create near-term growth opportunities, particularly with the product Rezzayo, which is in late-stage development for additional indications [13][14] Competitive Landscape - CorMedix faces competition from major players like Pfizer and Amphastar Pharmaceuticals, which could leverage their resources to enter the catheter-related infection prevention market [15][18][19] - The reliance on DefenCath for revenue raises concerns about the company's long-term growth potential amid increasing competition [15][23] Valuation Metrics - CorMedix shares are trading at a price/book ratio of 1.69, below the industry average of 3.63 and its five-year mean of 3.34 [20] - Earnings estimates for 2025 have decreased from $2.87 to $2.80 per share, while 2026 estimates have dropped from $2.88 to $1.26 [21]

Core Insights - CorMedix's lead product, DefenCath, is the first and only FDA-approved antimicrobial catheter lock solution in the U.S., launched in 2024, primarily targeting catheter-related bloodstream infections in kidney failure patients undergoing hemodialysis [1][2] - DefenCath generated $167.6 million in net sales in the first nine months of 2025, with a unique market position supported by patent protection until 2033 [2][3] - CorMedix's acquisition of Melinta Therapeutics for $300 million aims to diversify revenue streams and enhance its presence in hospital acute care and infectious disease markets [3] Financial Performance - Preliminary unaudited pro forma net revenues for CorMedix in 2025 are approximately $400 million, aligning with the company's guidance of $390 million to $410 million [3] - For 2026, CorMedix has provided revenue guidance of $300-$320 million, with DefenCath expected to contribute $150-$170 million [4][10] - Adjusted EBITDA for 2026 is projected to be between $100 million and $125 million [5] Market Dynamics - DefenCath's sales are expected to be stronger in the first half of 2026, but ongoing pricing pressure and flat usage among existing customers may hinder growth [5][10] - Competition from major players like Pfizer and Amphastar Pharmaceuticals poses a risk, as they could leverage their resources to enter the catheter-related infection prevention market [6][9][11] Stock Performance and Valuation - CorMedix's stock has decreased by 36.1% over the past six months, underperforming the industry growth of 18.7% [12] - The company's shares are trading at a price/book ratio of 1.57, below the industry average of 3.58, indicating a discount in valuation [13] - Earnings estimates for 2025 have decreased from $2.87 to $2.82 per share, while 2026 estimates have dropped from $2.88 to $1.78 [14]

Core Insights - CorMedix's lead product, DefenCath, is the first and only FDA-approved antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections (CRBSIs) in adult patients undergoing chronic hemodialysis [1][10] - DefenCath was launched in 2024 and is protected by patents until 2033, with plans for label expansion into total parenteral nutrition [2] - The company reported preliminary revenues of approximately $127 million for Q4 2025 and $310 million for the full year, with adjusted EBITDA expected between $77-$81 million for Q4 2025 [4][6] Product and Market Position - DefenCath's unique market position as the only FDA-approved therapy for a niche condition supports its revenue growth, with expectations of it being a key driver in Q4 2025 [2][10] - CorMedix's acquisition of Melinta Therapeutics for $300 million has diversified its revenue streams and strengthened its presence in hospital acute care and infectious disease markets, contributing $12.8 million in revenues in Q3 2025 [3] Financial Performance - Pro forma net revenues for full-year 2025 were around $400 million, with cash and short-term investments reported at approximately $148 million as of December 31, 2025, indicating improved financial flexibility [5] - For 2026, total revenue expectations are between $300-$320 million, with DefenCath projected to contribute $150-$170 million [6] Competitive Landscape - CorMedix faces strong competition from established players in the heparin market, such as Pfizer and Amphastar Pharmaceuticals, which could pose risks to its market advantage [7][9] - Major competitors have the potential to enter the CRBSI prevention market, which could challenge CorMedix's growth outlook [8][12] Stock Performance and Valuation - CorMedix's stock has declined by 36.3% over the past six months, underperforming the industry growth of 21.1% [13] - The company's shares are trading at a price/book ratio of 1.49, lower than the industry average of 3.56, indicating a discount in valuation [14] - Earnings estimates for 2025 have increased from $2.57 to $2.85 per share, while estimates for 2026 have decreased from $2.72 to $2.37 [17]

Core Viewpoint - Amphastar Pharmaceuticals is transitioning towards higher-value proprietary products while maintaining a focus on internal development and strategic acquisitions to enhance growth and profitability [2][5][13]. Growth Strategy - The company's growth strategy is two-pronged: internal development and strategic acquisitions, including the transformative acquisition of Baqsimi and prior acquisitions like the Armstrong facility [1][3]. - Amphastar aims for a 50% proprietary product mix by 2026, shifting from a historical pipeline that was 63% generic [5][6]. Product Development and Pipeline - The company is advancing a peptide pipeline with several promising candidates, including AMP-007 (metered-dose inhaler) expected to launch in mid-2026 and AMP-004 (insulin aspart) projected for 2027 [4][10]. - Four new chemical entities (NCEs) are in development, showing promising preclinical or early clinical data [4][8]. Financial Projections - Peak sales guidance for Baqsimi is set at $250–$275 million, with expectations of mid-single-digit growth this year [3][14]. - The company plans to exit unprofitable international markets to improve margins and forecasts high single-digit growth for Primatene Mist [3][15]. Research and Development Focus - Amphastar consistently invests $60–$75 million annually in R&D, focusing on proprietary programs, including AMP-105 and AMP-107, which target significant market opportunities [8][12]. - The company is evolving its pipeline in response to increased competition in complex generics, aiming for a mix of 50% proprietary, 35% biosimilar, and 15% generic by 2026 [6][20]. Market Position and Competitive Advantage - The acquisition of Baqsimi has strengthened Amphastar's position in the proprietary commercial Rx market and expanded its international footprint [13][18]. - The company has captured a majority of the prescription market for ready-to-use glucagon and is focused on increasing penetration among insulin users [18][19].

Core Viewpoint - Amphastar Pharmaceuticals, Inc. will be presenting at the J.P. Morgan 2026 Healthcare Conference on January 14th, 2026, at 2:15 pm PT [1] Company Information - Jack Zhang, CEO and President of Amphastar Pharmaceuticals, will be presenting at the conference [1] - Bill Peters, CFO of Amphastar Pharmaceuticals, will also be presenting at the conference [1]

Core Insights - CorMedix (CRMD) acquired Melinta Therapeutics for $300 million in August 2025, diversifying its revenue base and reducing reliance on its primary product, DefenCath [1][12] - The acquisition added seven approved products to CRMD's portfolio, contributing $12.8 million to its revenue in Q3 2025 [2][12] - DefenCath, approved by the FDA in late 2023, generated $167.6 million in net sales during the first nine months of 2025 [3] Revenue and Growth Opportunities - The Melinta acquisition is expected to create near-term growth opportunities, particularly through Rezzayo, which targets a market exceeding $2 billion for antifungal prophylaxis [4] - CRMD raised its full-year 2025 pro forma net revenue guidance to $390-$410 million, up from a previous estimate of at least $375 million, reflecting strong momentum from DefenCath and early contributions from Melinta [5] Competitive Landscape - Despite strong adoption of DefenCath, competition from major players like Pfizer, Amphastar Pharmaceuticals, and others poses a risk to CRMD's market position [6][7] - These competitors have stronger pipelines and greater resources, which could challenge CorMedix's growth outlook [8] - If Pfizer or Amphastar expands into catheter-related infection prevention, CRMD may face significant competitive pressure [10] Stock Performance and Valuation - CRMD shares have decreased by 2.5% over the past six months, underperforming the industry, which has rallied by 26.8% [13] - The stock is trading at a discount to the industry, with a price/book ratio of 2.55 compared to the industry average of 3.68 [14] - Earnings estimates for 2025 have improved from $1.85 to $2.87 per share, and for 2026 from $2.49 to $2.88 [15]